Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 248-273-7 | CAS number: 27157-94-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Repeated dose toxicity test was done according to OECD Guideline 422 under GLP compliance. Crj strain rats were used. No test item-related influence was noted on the reproduction parameters in any treatment group. The qualitative sperm staging revealed no test item-related spermatogenic changes. NOAEL (no-observed-adverse-effect level): above 137.1/182.8 mg/kg b.w./day, p.o. Effects on the development of the F1 offspring (pups) NOAEL (no-observed-adverse-effect level): 45.7 mg/kg b.w./day, p.o.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: oral
- Remarks:
- combined repeated dose and reproduction / developmental screening
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2012
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
- Species:
- rat
- Strain:
- Crj: CD(SD)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories Research, Models and Services Germany GmbH, Sandhofer Weg 7, 97633 Sulzfeld
- Age at study initiation: 59 days
- Weight at study initiation: Males: 319.0 g to 353.1 g, Females: 209.8 g to 248.4 g
- Housing: singly (With the exception of the mating period) in MAKROLON cages (type III plus) with a basal surface of approx. 39 cm x 23 cm and a height of approx. 18 cm
- Diet (e.g. ad libitum): ssniff R-Z V1324 (ssniff Spezialdiäten GmbH, 59494 Soest, Germany) . The food was offered ad libitum with the exception of the night before the day of blood withdrawal for laboratory examination
- Water (e.g. ad libitum): Tap water was offered ad libitum
- Acclimation period: 7 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22°C ± 3°C
- Humidity (%): of 55% ± 15%
- Photoperiod (hrs dark / hrs light): 12 h d / 12 h l
IN-LIFE DATES: From: Males and females : September 5th 2012 To: Males:October 17, 2012 Females:November 3, 2012 - Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
The test item formulations were freshly prepared on each administration day.
VEHICLE
- Concentration in vehicle: Variable, the dose of the test item was adjusted to the animal's actual body weight daily.
- Amount of vehicle: 10 mL/kg b.w./day
- Lot/batch no.: Batch no.: 11078709, Caesar & Loretz GmbH, 40721 Hilden, Germany. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- For the analysis of the test item-vehicle mixtures samples of approx. 2 x 1 mL were taken at the following time points and stored at ≤ minus 20°C until analysis at LPT:
Start of treatment period:
Concentration and stability:
Immediately after preparation of the test item vehicle mixtures as well as 8 and 24 hours after storage of the test item preparations at roomtemperature:
3 samples/dose level group (groups 2 to 4)
Number of samples: 3 x 4 = 12
Homogeneity:
At start of administration, during (middle) administration and before administration to the last animal of each dose level group:
3 samples/dose level group (groups 2 to 4).
Number of samples: 3 x 4 = 12
End of treatment period:
Concentration:
During treatment with the test item always before administration to the last animal/dose level group:
1 sample/dose level group (groups 2 to 4).
Number of samples: TD 28 (1 x 3) = 3
Number of samples: TD 41 (1 x 3) = 3
Sum of all samples: 30
Sum of all aliquots: 60
The samples were labelled with the study number, test item, test species, type of sample, aliquot number, concentration, test day, sampling time and date. - Duration of treatment / exposure:
- Males
The daily administration of the test item started two weeks before mating and lasted until the day before sacrifice (considering a minimum total dosing period of at least 28 days).
Females
The daily administration of the test item started two weeks before mating and lasted up to at least day 3 of lactation. - Frequency of treatment:
- once daily
- Dose / conc.:
- 0 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 13.7 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 45.7 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 137.1 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 182.2 mg/kg bw/day (actual dose received)
- Remarks:
- The high dose level was increased from 137.1 mg/kg to 182.8 mg/kg on test day 18, because the effects observed with 137.1 mg/kg after 2 weeks appeared to be too slight.
- No. of animals per sex per dose:
- 80 animals (40 male and 40 female rats),10 animals/sex/group.
A sufficient number to grant at least 8 pregnant females per group for evaluation of the F0 generation. - Control animals:
- yes, concurrent vehicle
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: at least daily, The frequency was increased when signs of toxicity were observed.
Cageside observations included skin/fur, eyes, mucous membranes, respiratory and circulatory systems, somatomotor activity and behaviour patterns. The onset, intensity and duration of any signs observed were recorded.
Individual animals were observed before and after dosing at each time of dosing for any signs of behavioural changes, reaction to treatment or illness.
In addition, animals were checked regularly throughout the working day from 7:00 a.m. to 3:45 p.m. On Saturdays and Sundays animals were checked regularly from 7:00 a.m. to 11:00 a.m. with a final check performed at approximately 3:30 p.m.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: at least daily, The frequency was increased when signs of toxicity were observed.
Additionally, once before the first exposure (to allow within-subject comparisons) and once a week thereafter, detailed clinical observations were made in all animals outside the home cage in a standard arena and at the same time, each time preferably by observers unaware of the treatment. Signs noted included changes in skin, fur, eyes, mucous membranes, occurrence of secretions and excretions and autonomic activity (e.g. lacrimation, piloerection, pupil size, and unusual respiratory pattern). Changes in gait, posture and response to handling as well as the presence of clonic or tonic movements, stereotypies (e.g. excessive grooming, repetitive circling), difficult or prolonged parturition or bizarre behaviour (e.g. selfmutilation, walking backwards) were also recorded.
Dated and signed records of appearance, change, and disappearance of clinical signs were maintained on clinical history sheets for individual animals.
BODY WEIGHT: Yes
- Time schedule for examinations: Males and females were weighed on the first day of dosing, weekly thereafter and at termination. During gestation, females were weighed on days 0, 7, 14 and 20 and within 24 hours of parturition (day 1 post-partum) and day 4 post-partum. Bodyweights were recorded individually for each adult animal.
The pups were weighed within 24 hours of parturition (day 1 post-partum) and on day 4 post-partum.
HAEMATOLOGY: Yes
- Time schedule for collection of blood: At the end of the pre-mating period
- Under anaesthesia: Yes
- Animals fasted: Yes
- How many animals: 5 male and 5 female animals randomly selected from each group
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: At the end of the pre-mating period
- Animals fasted: Yes
- How many animals: 5 male and 5 female animals randomly selected from each group
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: Shortly before scheduled sacrifice
- Dose groups that were examined: 5 males and 5 females per group
- Battery of functions tested: Screening of sensory reactiviity to simuli of different types (eg. auditory, visual and proprioceptive sitimuli), grip strength and motor activity. - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes - Statistics:
- Toxicology and pathology data were captured, whenever possible, using the depart-mental computerized systems (Provantis® Integrated preclinical software, version 8.2.0, Instem LSS Ltd.). Raw data not fully compatible with the computerized systems were maintained on paper according to appropriate SOPs.
For all numerical values homogeneity of variances was tested by using the BARTLETT chi-square test. If the variances were homogeneous, the DUNNETT test (p ≤ 0.01) was used to compare the experimental groups with the control group. - Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- FO generation:
Male animals:
At the high dose level (137.1/182.8 mg Cresyl-P1/kg b.w./day) slight or moderate salivation was noted in 5 of 10 animals between test days 5 and 8 and at the end of the study between test days 41 and 43. Piloerection was noted for 2 of 10 animals between test days 19 and 24.
Female animals:
At the high dose level (137.1/182.8 mg Cresyl- P1/kg b.w./day) slight or moderate salivation was noted in 2 of 10 animals during the second test week with a duration of 1 or 2 days. Animal no. 77 showed a slight salivation on gestation day 21 and animal no. 71 showed a moderate salivation on lactation day 3. - Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- No test item-related mortality was noted.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Male animals:
In the high dose group (137.1/182.8 mg Cresyl-P1/kg b.w./day) a decreased body weight was noted from test day 8 until test day 42, reaching statistical significance (p≤0.05) on test days 29, 36 and on test day 42 (p≤0.01), with a maximum reduction of 10.9% in comparison to the control rats.
Body weight gain was reduced in the high dose group (137.1/182.8 mg Cresyl-P1/kg b.w./day) during the whole study, reaching statistical significance at the end of the first test week on test day 8 (p≤0.01) and test days 29, 36 (p≤0.05) and test day 42 (p≤0.01).
Female animals:
At the high dose level (137.1/182.8 mg Cresyl-P1/kg b.w./day) a slightly decreased body weight was noted from the end of the gestation period (gestation day 20) until the end of the lactation period, reaching statistical significance (p≤0.05) on lactation day 4, with a maximum reduction of 8.1% in comparison to the control rats.
This slight decrease in body weight was not reflected by a reduction of body weight gain. - Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- A statistically significant reduction in food consumption compared to the control (at p ≤ 0.01) was noted in the high dose group (137.1/182.8 mg Cresyl-P1/kg b.w./day during the first test week.
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Male animals:
In the high dose group (137.1/182.8 mg Cresyl-P1/kg b.w./day) a statistically significant (p ≤ 0.05) decrease was noted in the albumin and in the total protein concentration.
Female animals:
No test item-related influence was noted. - Behaviour (functional findings):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Male and female animals:
The histomorphological examination revealed a mild to moderate squamous cell hyperplasia with mild to moderate hyperkeratosis in the forestomach of the male and female rats of the high dose groups (137.1/182.8 mg Cresyl-P1/kg b.w./day). These lesions were considered to be test item-related.
An additional examination of the forestomach of the male and female rats of the low and intermediate dose groups (13.7 and 45.7 mg Cresyl-P1/kg b.w./day) revealed no changes.
Spermatogenesis was not affected in the high dose group (137.1/182.8 mg Cresyl-P1/kg b.w./day). - Key result
- Dose descriptor:
- NOAEL
- Effect level:
- ca. 45.7 mg/kg bw/day (actual dose received)
- Based on:
- act. ingr.
- Sex:
- male/female
- Basis for effect level:
- other: Effects on the F0-generation
- Key result
- Critical effects observed:
- not specified
- Conclusions:
- NOAEL (no-observed-adverse-effect level): 45.7 mg/kg b.w./day, p.o.
Effects on reproductive toxicity:
No test item-related influence was noted on the reproduction parameters in any treatment group.
The qualitative sperm staging revealed no test item-related spermatogenic changes
NOAEL (no-observed-adverse-effect level): above 137.1/182.8 mg/kg b.w./day, p.o.
Effects on the development of the F1 offspring (pups)
NOAEL (no-observed-adverse-effect level): 45.7 mg/kg b.w./day, p.o. - Executive summary:
Repeated dose toxicity test was done according to OECD Guideline 422 under GLP compliance. Crj strain rats were used. No test item-related influence was noted on the reproduction parameters in any treatment group. The qualitative sperm staging revealed no test item-related spermatogenic changes. NOAEL (no-observed-adverse-effect level): above 137.1/182.8 mg/kg b.w./day, p.o. Effects on the development of the F1 offspring (pups) NOAEL (no-observed-adverse-effect level): 45.7 mg/kg b.w./day, p.o.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 45.7 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- Good quality
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Justification for classification or non-classification
No classification is warranted based on the findings in the OECD 422 study according to Regulation (EC) No 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.